These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20076850)

  • 21. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
    White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW
    Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
    Petersen P; Grind M; Adler J;
    J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
    Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
    Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
    Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
    Thromb Haemost; 2009 May; 101(5):938-42. PubMed ID: 19404548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
    Gomberg-Maitland M; Wenger NK; Feyzi J; Lengyel M; Volgman AS; Petersen P; Frison L; Halperin JL
    Eur Heart J; 2006 Aug; 27(16):1947-53. PubMed ID: 16774980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
    Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
    JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J; Mattsson C; Inghardt T; Elg M
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation.
    Pengo V; Cucchini U; Denas G; Davidson BL; Marzot F; Jose SP; Iliceto S
    Thromb Haemost; 2010 Feb; 103(2):442-9. PubMed ID: 20076843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
    Stewart RA
    Curr Opin Cardiol; 2011 Jul; 26(4):294-9. PubMed ID: 21537165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.